Make ZURZUVAE®
(zuranolone) your treatment choice for
women with
postpartum depression (PPD)

Select each hypothetical profile below to explore the symptoms of each woman with PPD and see why ZURZUVAE may be appropriate for them*

“I love my baby so much, but I feel overwhelmed and anxious all the time. I can’t stop thinking about everything that could go wrong. Will this ever get better?”

Visit notes:

  • First-time mom; thought she just had the baby blues
  • Experiencing persistent symptoms
  • Mom is staying to help with the baby
  • No history of depression or antidepressant use
  • Worried about what her family will think if she takes medication
  • Would like to consider a short-term treatment option

*All treatment decisions should be up to the discretion of the HCP and patient as each patient's situation may vary. These are not all the symptoms of PPD.
“I used to rely on walks to ease my anxiety. Now, I can't even bring myself to go.“
  • Loss of interest in activities
“I have trouble sleeping, even when she’s sleeping soundly. I keep getting up to check the baby monitor. I know she’s fine, but I just can’t relax.“
  • Insomnia ​
  • Psychomotor agitation​
“I keep imagining scary things, like her getting sick or me dropping her. These thoughts just pop into my head and I can’t make them stop.”
  • Intrusive thoughts†
  • Anxiety†
“I feel like I’m failing her already. I should be enjoying this time, but I’m always tense and second-guessing myself.”
  • Feelings of worthlessness​
  • Indecisiveness

These profile quotes are based on actual patient responses regarding PPD symptoms from Supernus Pharmaceuticals and Biogen market research from 2023–2025. These are not all the symptoms of PPD.

†Additional symptoms not listed in the DSM-5-TR® criteria.1,2

Lina's OBGYN made a PPD diagnosis after determining she met the DSM-5-TR® criteria

  • Depressed mood most of the day​
  • Loss of interest/pleasure in almost all activities most of the day​
  • Significant change in weight or appetite​
  • Insomnia or hypersomnia​
  • Psychomotor agitation or retardation​
  • Fatigue or loss of energy​
  • Feelings of worthlessness or excessive guilt​
  • Difficulty concentrating or making decisions​
  • Thoughts of death or suicidal ideation​
DSM-5-TR® criteria3

For patients to meet the DSM-5-TR® criteria for a major depressive episode with peripartum onset, they must have 5 or more of the above symptoms nearly every day‡ during the same 2-week period and change from previous functioning. At least 1 symptom must be either depressed mood or loss of interest/pleasure.

Additional criteria:

  • Symptoms cause clinically significant distress or impairment in social, occupational, or other important areas of functioning​
  • Episode is not attributable to the physiological effects of a substance or to another medical condition​
  • Symptom onset occurs during pregnancy or within 4 weeks after delivery​

‡”Nearly every day” does not apply to weight gain and recurrent suicidal thoughts or actions or recurrent thoughts of death.​

These are not the complete diagnostic criteria for PPD. The criteria listed here are adapted from the DSM-5-TR®. DSM-5® is a registered trademark of the American Psychiatric Association.

What could a treatment with just 14 days of dosing mean for patients like Lina?

“Why can’t they all just leave me alone for five minutes? I love them, so why do I feel like I could scream? This anger feels like it's overtaking me.“

Visit notes:

  • Has 2 additional kids
  • Sister is staying with her to help care for the older kids
  • Prescribed an antidepressant prior to pregnancy, which she continued throughout
  • Noticing new symptoms that worry her
  • Wants a treatment option that works quickly to improve her symptoms
  • Doesn't want to lose the progress she's already made

*All treatment decisions should be up to the discretion of the HCP and patient as each patient's situation may vary. These are not all the symptoms of PPD.
“I keep thinking, ‘Is this my life?’ It feels hopeless sometimes—and then I feel guilty for even feeling that way.”
  • Depressed mood
  • Feelings of guilt
“I get so angry out of nowhere. The stress of it all has me snapping at my kids, and I hate that. I feel like something’s wrong with me.“
  • Irritability†
  • Uncontrollable anger†
“I wake up feeling drained. The day hasn’t even started, and I feel like I’m bracing for a fight I don’t have the energy for.”
  • Loss of energy
  • Insomnia
“Every decision feels overwhelming, and I can’t focus on any of them. By the end of the day, I'm at my breaking point.”
  • Indecisiveness
  • Difficulty concentrating

These profile quotes are based on actual patient responses regarding PPD symptoms from Supernus Pharmaceuticals and Biogen market research from 2023–2025. These are not all the symptoms of PPD.

†Additional symptoms not listed in the DSM-5-TR® criteria.2,4

Ava's HCP made a PPD diagnosis after determining she met the DSM-5-TR® criteria

  • Depressed mood most of the day​
  • Loss of interest/pleasure in almost all activities most of the day​
  • Significant change in weight or appetite​
  • Insomnia or hypersomnia​
  • Psychomotor agitation or retardation​
  • Fatigue or loss of energy​
  • Feelings of worthlessness or excessive guilt​
  • Difficulty concentrating or making decisions​
  • Thoughts of death or suicidal ideation​
DSM-5-TR® criteria3

For patients to meet the DSM-5-TR® criteria for a major depressive episode with peripartum onset, they must have 5 or more of the above symptoms nearly every day‡ during the same 2-week period and change from previous functioning. At least 1 symptom must be either depressed mood or loss of interest/pleasure.

Additional criteria:

  • Symptoms cause clinically significant distress or impairment in social, occupational, or other important areas of functioning​
  • Episode is not attributable to the physiological effects of a substance or to another medical condition​
  • Symptom onset occurs during pregnancy or within 4 weeks after delivery​

‡”Nearly every day” does not apply to weight gain and recurrent suicidal thoughts or actions or recurrent thoughts of death.​

These are not the complete diagnostic criteria for PPD. The criteria listed here are adapted from the DSM-5-TR®. DSM-5® is a registered trademark of the American Psychiatric Association.

What could a treatment that may offer rapid symptom relief5,6 mean for patients like Ava?​

“I thought I'd be happy, but instead I feel so down and disconnected—like I'm watching life from the outside and can't connect, not even with my baby.“

Visit notes:

  • Recently welcomed her second baby
  • Partner is at home on leave to help
  • Took an antidepressant previously, but is not currently on treatment
  • After baby arrived, noticed sadness starting to creep back in
  • Looking for a different treatment option than her previous antidepressant
  • Wants something that will work quickly to improve her symptoms

*All treatment decisions should be up to the discretion of the HCP and patient as each patient's situation may vary. These are not all the symptoms of PPD.
“I cry almost every day, and I don’t even know why. I feel like I’m just going through the motions—nothing brings me joy anymore.”
  • Depressed mood
  • Loss of interest in activities
“I should feel something. I should want to hold him, right? I keep waiting for that moment when it all clicks, but it hasn’t come. I feel awful about it.”
  • Trouble bonding with baby†​
  • Feelings of guilt
“I’m exhausted all the time. Even when I get sleep, I’m dragging myself through the day. Eating is the last thing I feel like doing.”
  • Fatigue
  • Loss of appetite

These profile quotes are based on actual patient responses regarding PPD symptoms from Supernus Pharmaceuticals and Biogen market research from 2023–2025. These are not all the symptoms of PPD.

†Additional symptoms not listed in the DSM-5-TR® criteria.4

Kiera's nurse practitioner made a PPD diagnosis after determining she met the DSM-5-TR® criteria

  • Depressed mood most of the day​
  • Loss of interest/pleasure in almost all activities most of the day​
  • Significant change in weight or appetite​
  • Insomnia or hypersomnia​
  • Psychomotor agitation or retardation​
  • Fatigue or loss of energy​
  • Feelings of worthlessness or excessive guilt​
  • Difficulty concentrating or making decisions​
  • Thoughts of death or suicidal ideation​
DSM-5-TR® criteria3

For patients to meet the DSM-5-TR® criteria for a major depressive episode with peripartum onset, they must have 5 or more of the above symptoms nearly every day‡ during the same 2-week period and change from previous functioning. At least 1 symptom must be either depressed mood or loss of interest/pleasure.

Additional criteria:

  • Symptoms cause clinically significant distress or impairment in social, occupational, or other important areas of functioning​
  • Episode is not attributable to the physiological effects of a substance or to another medical condition​
  • Symptom onset occurs during pregnancy or within 4 weeks after delivery​

‡”Nearly every day” does not apply to weight gain and recurrent suicidal thoughts or actions or recurrent thoughts of death.​

These are not the complete diagnostic criteria for PPD. The criteria listed here are adapted from the DSM-5-TR®. DSM-5® is a registered trademark of the American Psychiatric Association.

What could a novel 14-day treatment that’s specifically indicated for PPD5 mean for patients like Kiera?​

Getting patients started

Learn about the 3 steps to get women with PPD started on ZURZUVAE
Why conversations matter

See why it's important to keep postpartum depression top of mind

Sign up to receive more information about ZURZUVAE or request live support
Request information

References: 1. Lawrence PJ, Craske MG, Kempton C, Stewart A, Stein A. Intrusive thoughts and images of intentional harm to infants in the context of maternal postnatal depression, anxiety and OCD. British J Gen Practice. 2017;67:376-377. 2. Thurgood S, Avery DM, Williamson L. Postpartum depression (PPD). Am Clin Med. 2009;6:17-22. 3. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed, Text Revision. American Psychiatric Publishing; 2022. 4. Perinatal Depression. National Institutes of Mental Health. https://www.nimh.nih.gov/health/publications/perinatal-depression. Accessed January 7, 2026. 5. ZURZUVAE Prescribing Information. Cambridge, MA: Biogen and Sage Therapeutics, Inc. 6. Deligiannidis KM, Meltzer-Brody S, Maximos B, et al. Zuranolone for the Treatment of Postpartum Depression. Am J Psych. 2023;180(9):668-675.

INDICATION

ZURZUVAE® (zuranolone) is indicated for the treatment of postpartum depression (PPD) in adults.

 

IMPORTANT SAFETY INFORMATION

WARNING: IMPAIRED ABILITY TO DRIVE OR ENGAGE IN OTHER POTENTIALLY HAZARDOUS ACTIVITIES

ZURZUVAE causes driving impairment due to central nervous system (CNS) depressant effects.

Advise patients not to drive or engage in other potentially hazardous activities until at least 12 hours after ZURZUVAE administration for the duration of the 14-day treatment course. Inform patients that they may not be able to assess their own driving competence, or the degree of driving impairment caused by ZURZUVAE.

 

WARNINGS AND PRECAUTIONS

Impaired Ability to Drive or Engage in Other Potentially Hazardous Activities

  • ZURZUVAE causes driving impairment due to central nervous system (CNS) depressant effects
  • Advise patients not to drive a motor vehicle or engage in other potentially hazardous activities requiring complete mental alertness, such as operating machinery, until at least 12 hours after ZURZUVAE administration for the duration of the 14-day treatment course. Inform patients that they may not be able to assess their own driving competence or the degree of driving impairment caused by ZURZUVAE

Central Nervous System Depressant Effects

  • ZURZUVAE can cause CNS depressant effects such as somnolence and confusion
  • Somnolence developed in 36% of patients who received ZURZUVAE (50 mg) and in 6% of patients who received placebo daily. Some ZURZUVAE-treated patients developed confusional state. One of these cases was severe, and was also associated with somnolence, dizziness, and gait disturbance
  • A higher percentage of ZURZUVAE-treated patients, compared to placebo-treated patients, experienced somnolence, dizziness, or confusion that required dosage reduction, interruption, or discontinuation
  • Because ZURZUVAE can cause CNS depressant effects, patients may be at higher risk of falls
  • Other CNS depressants such as alcohol, benzodiazepines, opioids, tricyclic antidepressants, or drugs that increase zuranolone concentration, may increase impairment of psychomotor performance or CNS depressant effects such as somnolence, cognitive impairment, and the risk of respiratory depression in ZURZUVAE-treated patients
  • To reduce the risk of CNS depressant effects and/or mitigate CNS depressant effects that occurs with ZURZUVAE treatment:
    • If patients develop CNS depressant effects, consider dosage reduction or discontinuation of ZURZUVAE
    • If use with another CNS depressant is unavoidable, consider dosage reduction
    • Reduce the ZURZUVAE dosage in patients taking strong CYP3A4 inhibitors

Suicidal Thoughts and Behavior

  • In pooled analyses of placebo-controlled trials of chronically administered antidepressant drugs (SSRIs and other antidepressant classes) that included approximately 77,000 adult patients and 4,500 pediatric patients, the incidence of suicidal thoughts and behaviors in antidepressant-treated patients age 24 years and younger was greater than in placebo-treated patients. There was considerable variation in risk of suicidal thoughts and behaviors among drugs, but there was an increased risk identified in young patients for most drugs studied. There were differences in absolute risk of suicidal thoughts and behaviors across the different indications, with the highest incidence in patients with major depressive disorder (MDD)
  • ZURZUVAE does not directly affect monoaminergic systems. Consider changing the therapeutic regimen, including discontinuing ZURZUVAE, in patients whose depression becomes worse or who experience emergent suicidal thoughts and behaviors

Embryo-fetal Toxicity

  • Based on findings from animal studies, ZURZUVAE may cause fetal harm when administered to a pregnant woman
  • Advise a pregnant woman of the potential risk to an infant exposed to ZURZUVAE in utero. Advise females of reproductive potential to use effective contraception during treatment with ZURZUVAE and for one week after the final dose
 

ADVERSE REACTIONS

  • The most common adverse reactions (≥5% and greater than placebo) in ZURZUVAE-treated patients were somnolence, dizziness, diarrhea, fatigue, nasopharyngitis, and urinary tract infection
 

DRUG INTERACTIONS

CNS Depressant Drugs and Alcohol

  • Caution should be used when ZURZUVAE is administered in combination with other CNS drugs or alcohol. If use with another CNS depressant is unavoidable, consider dosage reduction

Strong CYP3A4 Inhibitors

  • Reduce the ZURZUVAE dosage when used with a strong CYP3A4 inhibitor

CYP3A4 Inducers

  • Avoid concomitant use of ZURZUVAE with CYP3A4 inducers
 

USE IN SPECIFIC POPULATIONS

Pregnancy

  • There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to antidepressants, including ZURZUVAE, during pregnancy. Healthcare providers are encouraged to register patients by calling the National Pregnancy Registry for Antidepressants at 1-844-405-6185 or visiting online at https://womensmentalhealth.org/research/pregnancyregistry/antidepressants/
  • Based on findings from animal studies, ZURZUVAE may cause fetal harm. Advise pregnant women of the potential risk to a fetus. Available data on ZURZUVAE use in pregnant women from the clinical development program are insufficient to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes

Lactation

  • Available data from a clinical lactation study in 14 women indicate that zuranolone is present in low levels in human milk. There are no data on the effects of zuranolone on a breastfed infant and limited data on the effects on milk production
  • The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for ZURZUVAE and any potential adverse effects on the breastfed child from ZURZUVAE or from the underlying maternal condition

Hepatic Impairment

  • The recommended ZURZUVAE dosage in patients with severe hepatic impairment (Child-Pugh C) is lower than patients with normal hepatic function

Renal Impairment

  • The recommended ZURZUVAE dosage in patients with moderate and severe renal impairment is lower than those with normal renal function
 

DRUG ABUSE AND DEPENDENCE

  • ZURZUVAE contains zuranolone, a Schedule IV controlled substance
  • Zuranolone has abuse potential with associated risks of misuse, abuse, and substance use disorder including addiction
  • ZURZUVAE may produce physical dependence
 

Please see full Prescribing Information, including Boxed Warning.

Terms of Use Notice to CA Residents Privacy Policy Contact Us Cookie Policy Unsubscribe Pricing Disclosures

This site is intended for US healthcare professionals.

ZURZUVAE and the ZURZUVAE logo are trademarks of Sage Therapeutics licensed to Supernus Pharmaceuticals, Inc. BIOGEN and the BIOGEN logo are registered trademarks of Biogen Inc. SUPERNUS PHARMACEUTICALS and the SUPERNUS PHARMACEUTICALS logo are registered trademarks of Supernus Pharmaceuticals, Inc. All other trademarks referenced herein are the property of their respective owners.

©2026 Supernus Pharmaceuticals, Inc. All rights reserved.


©2026 Biogen. All rights reserved. ZUR-US-0299v7 04/26